In an adult patient presenting with chest pain suggestive of acute coronary syndrome, should the discharge aspirin dose be 81 mg (low‑dose) or 325 mg?

Discharge Aspirin Dose: 81 mg Daily

For patients discharged after acute coronary syndrome (ACS), aspirin 81 mg (low-dose) daily should be the standard maintenance dose. This recommendation is supported by the most recent and highest-quality guidelines, which demonstrate equivalent cardiovascular protection with significantly reduced bleeding risk compared to higher doses.

Guideline Recommendations

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline provides the most current evidence-based recommendation: after an initial loading dose of 162-325 mg, patients should transition to daily low-dose aspirin (75-100 mg) for maintenance therapy 1. This represents a clear evolution from older guidelines that permitted doses up to 325 mg daily.

The 2014 AHA/ACC NSTE-ACS guidelines established that while maintenance doses of 81-325 mg daily were acceptable, 81 mg daily is reasonable to use in preference to higher maintenance doses (Class IIa recommendation) 2, 3. Importantly, these guidelines specifically mandate 81 mg daily for patients treated with ticagrelor 2, 3.

Evidence Supporting Low-Dose Aspirin

Efficacy Data

The CURRENT-OASIS 7 trial directly compared aspirin dosing in 25,086 ACS patients undergoing invasive management 4. This landmark study found:

• No significant difference in cardiovascular death, MI, or stroke between higher-dose (300-325 mg) and lower-dose (75-100 mg) aspirin
• Primary outcome: 4.2% vs 4.4% (HR 0.97,95% CI 0.86-1.09, p=0.61)
• This establishes therapeutic equivalence for ischemic protection

Bleeding Risk

Multiple high-quality studies demonstrate increased bleeding with higher aspirin doses:

TRANSLATE-ACS study (10,213 post-PCI MI patients) 5:

• 325 mg vs 81 mg showed no difference in major adverse cardiovascular events (adjusted HR 0.99,95% CI 0.85-1.17)
• Significantly increased bleeding with 325 mg (adjusted OR 1.19,95% CI 1.06-1.33)
• Bleeding events were primarily minor (BARC 1-2) but clinically meaningful

HORIZONS-AMI trial (2,851 STEMI patients) 6:

• High-dose aspirin (>200 mg) was an independent predictor of major bleeding (HR 2.80,95% CI 1.31-5.99, p=0.008)
• No reduction in ischemic events with higher doses
• Increased rates of reinfarction and stent thrombosis paradoxically observed with high-dose aspirin

CURE trial subanalysis 7:

• Bleeding risk increased progressively with aspirin dose (≤100 mg: 1.9%, 101-199 mg: 2.8%, ≥200 mg: 3.7%)
• Adjusted HR for major bleeding with highest vs lowest dose: 1.7 (95% CI 1.36-2.20)
• Efficacy was maintained across all dose ranges

Clinical Algorithm for Discharge Aspirin Dosing

Standard approach:

1. Loading dose: 162-325 mg non-enteric coated, chewed if possible 1, 3
2. Maintenance dose: Transition to 81 mg (or 75-100 mg) daily starting the day after discharge
3. Duration: Indefinite continuation unless contraindicated

Special considerations:

• With ticagrelor: Mandatory 81 mg daily (higher doses reduce ticagrelor efficacy) 2, 3, 1
• With clopidogrel or prasugrel: 81 mg daily preferred, though up to 325 mg historically used 2, 3
• Post-PCI with stent: Some older protocols used 325 mg for 1-6 months post-stent, but current evidence supports 81 mg from discharge 1, 5
• High bleeding risk patients: 81 mg is particularly important to minimize bleeding while maintaining antiplatelet effect

Common Pitfalls to Avoid

1. Continuing high-dose aspirin long-term: The 325 mg loading dose should not be continued as maintenance therapy. This is a frequent error that increases bleeding without improving outcomes.

2. Using enteric-coated aspirin initially: Non-enteric coated formulations ensure faster absorption during the acute phase 3.

3. Dose escalation for perceived "high-risk" patients: Higher aspirin doses do not provide additional ischemic protection but do increase bleeding risk 5, 6, 4.

4. Ignoring P2Y12 inhibitor type: Ticagrelor specifically requires 81 mg aspirin; higher doses impair its effectiveness 2, 1.

Strength of Evidence

The recommendation for 81 mg daily maintenance aspirin is supported by:

• Class I, Level A evidence from the 2025 ACC/AHA guideline for low-dose aspirin maintenance 1
• Class IIa, Level B evidence from 2014 guidelines preferring 81 mg over higher doses 2, 3
• Large randomized controlled trial (CURRENT-OASIS 7) showing equivalence for efficacy 4
• Multiple observational studies consistently demonstrating increased bleeding with higher doses 5, 6, 7

The evidence is unequivocal: 81 mg daily provides equivalent cardiovascular protection with significantly less bleeding risk compared to 325 mg daily.